ClinicalTrials.gg
Not yet recruitingNCT07947134Updated Nov 18, 2026

A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours

A Phase 1/2 interventional study of GSK5864399 in Solid Tumours, sponsored by GlaxoSmithKline. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Colorectal Neoplasms by GlaxoSmithKline — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · GlaxoSmithKline.

Planned enrollment
4th of 15
155 · median 83
Started
2026
the only one that year
Phase 1/2
5 of 15
3 open now
Registered
15th of 15
by date

Among the 15 studies in Colorectal Neoplasms by GlaxoSmithKline, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 1/2, and was the 15th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 15 studies in Colorectal Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Colorectal Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.

03

Conditions studied

  • Solid Tumours

Keywords

  • GSK5864399
  • Advanced Solid Tumours
  • Metastatic Colorectal Cancer (mCRC)
  • Metastatic Non-Small Cell Lung Cancer (mNSCLC)
  • T-cell Engager
  • Carcinoembryonic Antigen-related cell adhesion molecule 5 (CEACAM5)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Is at least 18 years of age or the legal age of consent.
  • Has confirmed unresectable disease of either:

    • colorectal cancer that has progressed through at least 2
    • non-small cell lung cancer that has progressed through at least 1 prior line of systemic therapy
  • Has at least 1 target lesion per 1.1, as determined by the investigator.
  • Participants must provide Formalin-Fixed, Paraffin-Embedded (FFPE) tumour tissue sample taken from primary cancer or metastatic site.
  • Is willing to use adequate .
  • Is capable of giving signed .
  • Has an performance status of 0 or 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria

  • Has a (except disease under study) that has progressed or required active treatment within the past 24 months (with some exceptions).
  • Has had any major surgery within 28 days prior to first dose.
  • Has any history of prior or autologous bone marrow transplant or other solid organ transplant.
  • Has known sensitivity to study intervention components or or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • Has known active infectious disease or a serious infection within 4 weeks prior to the first dose.
  • Has a history (in prior year) of or uncontrolled cardiovascular disease.
  • Has untreated brain or Central Nervous System (CNS) or brain/ that have progressed.
  • Any evidence of small cell or sarcomatoid histology for the NSCLC participants.
  • Has a history of disease that has required systemic treatments in the 2 years prior to screening.
  • Has any active renal condition.
  • Has a history of discontinuing prior treatment due to TEAE of ILD/pneumonitis
  • Has a history of (non-infectious) Interstitial Lung Disease (ILD)/pneumonitis that required active treatment within 4 weeks before study-intervention administration.
  • Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy (with some exclusions).
  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of , or compliance to the study procedures.
  • Has symptomatic and/or progressive pleural metastases or confirmed malignant pleural effusions despite appropriate analgesia and thoracenteses respectively. Participants with previously treated pleural metastases/malignant pleural effusions with clinical stability demonstrated for at least 4 weeks prior to first dose are not excluded from participation.
  • Has received agents within 30 days prior to first dose of study intervention (or requires long term [30 days or longer]).
  • Has received any prior therapy targeting CEACAM5.
  • Has received any within 30 days of first dose. Vaccination against COVID-19 using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary. Messenger Ribonucleic acid (mRNA) and adenoviral-based COVID-19 vaccines are considered non-live. If a COVID-19 vaccine is administered at any time, the date of COVID-19 vaccination must be entered in the electronic Case Report Form (eCRF).
  • Has received any transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before first dose.
  • History of local radiotherapy within 2 weeks prior to the first dose of study intervention; more than 30% of bone marrow irradiation or extensive radiotherapy within 4 weeks before the first dose of study intervention.
  • Is currently enrolled or has participated in any other clinical study involving an study intervention or any other type of interventional medical research and/or has received treatment with any anticancer or investigational agent within 4 weeks prior to first dose. Participation in study follow-up part without IMP administration, non-interventional registry or epidemiological study is allowed.
  • Has a known (HIV) infection AND meets at least one of the following criteria:

    • Has documented evidence of plasma HIV-1 Ribonucleic Acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently \<50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
    • Has not had measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
    • Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
    • Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in full protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
    • Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
    • Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening. Participants with history of CDC Stage 3 disease (also known as AIDS defining disease are eligible provided all other applicable criteria are met) if the AIDS-defining disease has been treated and cured or is stable for at least 3 months prior to screening. Cutaneous Karposi's Sarcoma not requiring systemic therapy is not exclusionary.
  • Is unable to adhere to the protocol-defined schedule of assessments, including requirements for the follow-up period of the study.
  • Has an (ALT) or AST value >2.5x (ULN) and/or for participants with documented liver metastases/tumour infiltration has an ALT or AST value >5x ULN.
  • Has a total value >1.5x ULN. Participants with Gilbert's syndrome can be included with a total bilirubin value >1.5x ULN, provided direct bilirubin is ≤1.5x ULN and participant otherwise meets entry criteria.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Stable noncirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if the participant otherwise meets entry criteria.
  • Has documented presence of surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention. In Japan, the following modification is applied; Has documented presence of HBsAg, HBcAb, or Hepatitis B surface antibody (HBsAb) (except for presence of HBsAb attributable to previous vaccination) at screening or within 3 months prior to the first dose of study intervention. For participants with presence of HBsAb, Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) will be tested every 3 months.
  • Has a positive Virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention unless HCV RNA is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment. Participants with a positive HCV antibody test result due to prior resolved disease, including those who have undergone curative HCV treatment, can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria.
  • Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention. The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
  • Has baseline corrected for heart rate (QTc)>480 msec.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Drug: GSK5864399

  • Experimental
    Part 2: Dose Expansion

    Drug: GSK5864399

Interventions

  • DrugGSK5864399

    GSK5864399 will be administered

06

What researchers measure

Primary outcomes

  1. Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0

    Time frame: Up to approximately 155 weeks

  2. Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)

    Time frame: Up to approximately 155 weeks

  3. Part 1 & 2: Number of participants with changes in safety parameters

    Time frame: Up to approximately 155 weeks

  4. Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severity

    Time frame: Up to approximately 155 weeks

  5. Part 1 & 2: Number of participants with AEs leading to dose modifications

    Time frame: Up to approximately 155 weeks

  6. Part 1 & 2: Number of participants with a change from baseline in body weight

    Time frame: Up to approximately 155 weeks

  7. Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)

    Time frame: Up to approximately 155 weeks

  8. Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)

    Time frame: Up to approximately 155 weeks

  9. Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status

    Time frame: Up to approximately 155 weeks

  10. Part 2: Confirmed Objective Response Rate (cORR)

    cORR is defined as the proportion of participants who have achieved a Best of response (BOR) of Complete Response (CR) or Partial Response (PR) as assessed by the Investigator and confirmed by repeat assessments at least 4 weeks after the initial response is documented, according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1.

    Time frame: Up to approximately 155 weeks

Secondary outcomes

  1. Part 1& 2: Maximum concentration (Cmax) of GSK5864399

    Time frame: Up to approximately 161 weeks

  2. Part 1& 2: Time to maximum concentration (Tmax) of GSK5864399

    Time frame: Up to approximately 161 weeks

  3. Part 1& 2: Area under the concentration-time curve (AUC) of GSK5864399

    Time frame: Up to approximately 161 weeks

  4. Part 1& 2: Trough concentration (Ctrough) of GSK5864399

    Time frame: Up to approximately 161 weeks

  5. Part 2: Progression-free survival (PFS)

    PFS is defined as the time from date of randomization until the earliest date of documented disease progression as assessed by the Investigator according to RECIST1.1 or death due to any cause.

    Time frame: Up to approximately 161 weeks

  6. Part 2: Duration of Response (DoR)

    DoR is defined as the time from the date of the first documented objective response (CR/PR as assessed by the Investigator according to RECIST1.1) until the date of the first documented progression of disease (PD) or death, whichever is earlier.

    Time frame: Up to approximately 161 weeks

  7. Part 1 & 2: Number of participants with Anti-drug antibodies (ADA) against GSK5864399

    Time frame: Up to approximately 161 weeks

  8. Part 1 & 2: Titers of ADA against GSK5864399

    Time frame: Up to approximately 161 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 35 months later.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 35 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Nov 16, 2029
CompletionEst.
Dec 28, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947134
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Nov 16, 2029 (estimated)
Completion
Dec 28, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion